Skip to main content
Top

Investigational New Drugs

Issue 2/2004

Content (11 Articles)

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

George Wilding, David King, Kendra Tutsch, Marcia Pomplun, Chris Feierabend, Dona Alberti, Rhoda Arzoomanian

A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

Joseph P. Eder Jr, Rocio Garcia-Carbonero, Jeffrey W. Clark, Jeffrey G. Supko, Thomas A. Puchalski, David P. Ryan, Pamela Deluca, Antoinette Wozniak, Angela Campbell, John Rothermel, Patricia LoRusso

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

H.J.G. Desirée van den Bongard, Rolf W. Sparidans, David J.P. Critchley, Jos H. Beijnen, Jan H.M. Schellens

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

Lyly H. Lê, Charles Erlichman, Linda Pillon, Jake J. Thiessen, Andrew Day, Nancy Wainman, Elizabeth A. Eisenhauer, Malcolm J. Moore

Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

G. Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, Joel Sheinfeld, Dean Bajorin, Jacqueline Vuky, Stephanie Marion, Madhu Mazumdar, George J. Bosl, Robert J. Motzer

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

J. Philip Kuebler, Timothy Moore, James Pritchard, Eric Kraut

A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer

Michael Jefford, Michael Michael, Mark A. Rosenthal, Ian D. Davis, Michael Green, Bev McClure, Jennifer Smith, Brigid Waite, John Zalcberg

Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer

Nikolas Tsavaris, Christos Kosmas, Panagiotis Gouveris, Kostadinos Gennatas, Aris Polyzos, Despina Mouratidou, Heracles Tsipras, Helias Margaris, George Papastratis, Evanthia Tzima, Nikitas Papadoniou, Gavrilos Karatzas, Efstathios Papalambros

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine